{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:37:11Z","timestamp":1792071431039,"version":"4.4.0"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Prim Care Community Health"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Clinical trials show that doxycycline post-exposure prophylaxis (DoxyPEP) significantly reduces the risk of bacterial sexually transmitted infections (STIs), especially syphilis and chlamydia, in cisgender men who have sex with men and transgender women. Real-world data suggest DoxyPEP may be beneficial for other populations disproportionately affected by STIs. Given the ongoing STI epidemic we recommend discussing DoxyPEP with all eligible patients. We review clinical guidelines and practical considerations surrounding DoxyPEP, highlight areas for future research, and propose strategies for implementation.<\/jats:p>","DOI":"10.1177\/21501319251370497","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:54:33Z","timestamp":1757152473000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["DoxyPEP: Opportunities for Expansion"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5679-6277","authenticated-orcid":false,"given":"En-Ling","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1003-3995","authenticated-orcid":false,"given":"Jade","family":"Pagkas-Bather","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Hazra","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai T.","family":"Pho","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6805a1"},{"key":"e_1_3_2_3_2","unstructured":"Centers for Disease Control and Prevention. 2023 CDC data suggest the STI epidemic may be slowing. 2024. Accessed May 28 2025. https:\/\/www.cdc.gov\/media\/releases\/2024\/p1112-sti-slowing.html"},{"key":"e_1_3_2_4_2","unstructured":"Centers for Disease Control and Prevention. National Overview of STIs in 2023. 2024. Accessed May 28 2025. https:\/\/www.cdc.gov\/sti-statistics\/annual\/summary.html"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae062"},{"key":"e_1_3_2_6_2","unstructured":"Centers for Disease Control and Prevention. Impact of COVID-19 on STIs. 2024. Accessed May 28 2025. https:\/\/www.cdc.gov\/sti-statistics\/about\/impact-of-covid-19.html#:~:text=The%20COVID%2D19%20pandemic%20significantly of%20the%20pandemic%20on%20STIs"},{"key":"e_1_3_2_7_2","unstructured":"National Academies of Sciences Engineering and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Prevention and Control of Sexually Transmitted Infections in the United States; Crowley JS Geller AB Vermund SH eds. Sexually Transmitted Infections: Adopting a Sexual Health Paradigm. National Academies Press; 2021. 5 Intersection of HIV and STIs. Accessed on May 28 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK573161\/"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7302a1"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211934"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30725-9"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00236-6"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100871"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2024-056152"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf089"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000002095"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.7186"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002774"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-020-01198-7"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2023.08.014"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae527"},{"key":"e_1_3_2_21_2","unstructured":"Cieri-Hutcherson NE. 7 doxycycline side effects you should know about. 2024. Accessed May 28 2025. https:\/\/www.goodrx.com\/doxycycline-hyclate\/common-side-effects"},{"key":"e_1_3_2_22_2","unstructured":"San Francisco Department of Public Health. Updated recommendations for prescribing doxycycline post-exposure prophylaxis (Doxy-PEP). 2024. Accessed May 28 2025. https:\/\/www.sf.gov\/file\/updated-recommendations-prescribing-doxycycline-post-exposure-prophylaxis-doxy-pep"},{"key":"e_1_3_2_23_2","unstructured":"Howard Brown Health. DoxyPEP for STI Prevention. Accessed May 28 2025. https:\/\/howardbrown.org\/service\/doxypep\/"},{"key":"e_1_3_2_24_2","volume-title":"Doxycycline Post-Exposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infections","author":"DiMarco DE","year":"2024","unstructured":"DiMarco DE, Urban MA, Vail RM, et al. Doxycycline Post-Exposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infections. Johns Hopkins University; 2024."},{"key":"e_1_3_2_25_2","unstructured":"Centers for Disease Control and Prevention. County-level Syphilis Data. 2024. Accessed May 28 2025. https:\/\/www.cdc.gov\/sti-statistics\/county-level-syphilis-data\/index.html"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad488"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304007"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105037"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Abe S Mizushima D Ando N et al. Doxycycline pre-exposure prophylaxis prevents sexually transmitted infections without affecting vaginal bacterial flora in female sex workers. JAC Antimicrob Resist. 2025;7(2):dlaf054.","DOI":"10.1093\/jacamr\/dlaf054"},{"key":"e_1_3_2_30_2","unstructured":"U.S. Food and Drug Administration. Doxycycline Use of Pregnant and Lactating Women. 2017. Accessed May 28 2025. https:\/\/www.fda.gov\/drugs\/bioterrorism-and-drug-preparedness\/doxycycline-use-pregnant-and-lactating-women"},{"key":"e_1_3_2_31_2","unstructured":"Illinois Department of Public Health. Administration of Undesignated Asthma Medications in School. 2024. Accessed May 28 2025. https:\/\/dph.illinois.gov\/content\/dam\/soi\/en\/web\/idph\/resources\/topics-services\/diseases-and-conditions\/asthma\/albuterol-standing-order-02-29-24.pdf"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac009"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf089"},{"key":"e_1_3_2_34_2","unstructured":"Scott H. Drug resistance and DoxyPEP: Should we worry? 2023. Accessed May 28 2025. https:\/\/www.sfaf.org\/collections\/beta\/drug-resistance-and-doxy-pep-should-we-worry\/"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr370"}],"container-title":["Journal of Primary Care &amp; Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319251370497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21501319251370497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319251370497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:23:29Z","timestamp":1777508609000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21501319251370497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":34,"alternative-id":["10.1177\/21501319251370497"],"URL":"https:\/\/doi.org\/10.1177\/21501319251370497","relation":{},"ISSN":["2150-1319","2150-1327"],"issn-type":[{"value":"2150-1319","type":"print"},{"value":"2150-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"article-number":"21501319251370497"}}